Pharmaceuticals

Pulmonary Arterial Hypertension Market Forecast 2025–2034: Where Businesses Should Invest Next

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Pulmonary Arterial Hypertension Market By 2029?

The pulmonary arterial hypertension market has demonstrated substantial growth in recent years. Projections show this market expanding from $8.47 billion in 2024 to reach $9.15 billion in 2025, driven by an 8.0% compound annual growth rate (CAGR). This historical growth can be primarily attributed to factors such as heightened awareness and improved diagnosis of pulmonary arterial hypertension (PAH), a rise in healthcare spending, an expanding aging population, the broadening of pulmonary arterial hypertension treatment options, and an uptick in research and development initiatives within pulmonary hypertension.

The pulmonary arterial hypertension market is anticipated to experience robust expansion in the coming years, reaching $12.69 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.5%. This projected growth is fueled by the uptake of new therapies for pulmonary arterial hypertension, a greater focus on early detection and diagnosis, an expanding array of PAH drugs and treatments in development, the integration of precision medicine into PAH care, and the enhancement of healthcare infrastructure in developing economies. Significant trends during this forecast timeframe include improvements in medical imaging and diagnostic technologies, strategic collaborations and partnerships for drug innovation, patient-centered methodologies in pulmonary arterial hypertension management, and an increased adoption of combination therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp

Which Drivers Are Shaping The Pulmonary Arterial Hypertension Industry’s Market Share?

The rising prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. This increasing prevalence of PAH diseases and the associated hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500–1000 new cases each year, and Europe is expected to have similar incidence rates.

Which Key Segments Fueling The Pulmonary Arterial Hypertension Market?

The pulmonary arterial hypertension market covered in this report is segmented –

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators

2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational

3) By Distribution channel: Retail, Online

Subsegments:

1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan

2) By PDE-5 Inhibitors: Sildenafil, Tadalafil

3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost

4) By SGC Stimulators: Riociguat

Which Competitive Trends Are Defining The Pulmonary Arterial Hypertension Market Structure?

Trend 1. Major companies active in the pulmonary arterial hypertension market are creating advanced products, such as Winrevair, to improve treatment options and outcomes for patients with this serious condition. For instance, in March 2024, the US-based multinational pharmaceutical company Merck & Co. Inc. introduced Winrevair for treating adults with pulmonary arterial hypertension. Winrevair is the first therapy approved by the Food and Drug Administration (FDA), a US-based federal agency, that targets activin signaling for pulmonary arterial hypertension (PAH). This innovative treatment operates by restoring the balance between pro- and anti-proliferative signals, which assists in regulating the vascular cell proliferation associated with PAH. As a result, it introduces a novel class of therapy for this condition.

Which Key Players Are Driving Competition In The Pulmonary Arterial Hypertension Market?

Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

How Do Regional Market Performances Compare Within The Pulmonary Arterial Hypertension Industry?

North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Pulmonary Arterial Hypertension Market Report:

https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp

Browse Through More Reports Similar to the Global Pulmonary Arterial Hypertension Market 2025, By The Business Research Company

Respiratory Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-global-market-report

Anti Hypertensive Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Anticoagulant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795